TIROSINT-SOL Drug Patent Profile

When do Tirosint-sol patents expire, and what generic alternatives are available?

Tirosint-sol is a drug marketed by Ibsa and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in thirteen countries.

The generic ingredient in TIROSINT-SOL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tirosint-sol

A generic version of TIROSINT-SOL was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for TIROSINT-SOL

International Patents:	25
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIROSINT-SOL

Paragraph IV (Patent) Challenges for TIROSINT-SOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIROSINT-SOL	Oral Solution	levothyroxine sodium	13 mcg/mL 25 mcg/mL 50 mcg/mL 75 mcg/mL 88 mcg/mL 100 mcg/mL 112 mcg/mL 125 mcg/mL 137 mcg/mL 150 mcg/mL 175 mcg/mL 200 mcg/mL	206977	1	2022-09-30

US Patents and Regulatory Information for TIROSINT-SOL

TIROSINT-SOL is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-008	Dec 15, 2016		RX	Yes	No	11,241,382
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-005	Dec 15, 2016		RX	Yes	No	11,096,913		Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-010	Dec 15, 2016		RX	Yes	No	11,241,382
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-012	Dec 15, 2016		RX	Yes	Yes	10,537,538		Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-009	Dec 15, 2016		RX	Yes	No	11,241,382
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-011	Dec 15, 2016		RX	Yes	No	11,096,913		Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-004	Dec 15, 2016		RX	Yes	No	11,096,913		Y

International Patents for TIROSINT-SOL

See the table below for patents covering TIROSINT-SOL around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	3528847
Canada	3129627
Denmark	3528847
European Patent Office	3930703
Slovenia	3528847
World Intellectual Property Organization (WIPO)	2018073209
European Patent Office	4321214

Investment Scenario and Fundamentals Analysis for TIROSINT-SOL

Last updated: February 20, 2026

What Is TIROSINT-SOL?

TIROSINT-SOL (liothyronine sodium) is a synthetic form of triiodothyronine (T3), a thyroid hormone used primarily to treat hypothyroidism. It is marketed as an oral solution, providing an alternative to capsules for patients with thyroid hormone deficiencies. The drug is approved in multiple markets, including the United States, with regulatory approval processes completed by the FDA.

Market Overview and Demand Dynamics

The global hypothyroidism treatment market was valued at approximately USD 2.95 billion in 2022. It is projected to grow at a CAGR of 4% over the next five years, driven by increasing prevalence and improved diagnosis rates.

Prevalence and Patient Population

• Estimated 200 million people worldwide have hypothyroidism.
• In the US, roughly 4.6% of the population (around 14 million people) suffer from diagnosed hypothyroidism [1].
• Patients aged 60 and above account for the majority of cases.

Existing Treatments and Competitive Landscape

• Levothyroxine (T4) remains the standard treatment due to stability, cost, and long-term efficacy.
• Liothyronine (T3) formulations like TIROSINT-SOL address specific patient needs such as those with malabsorption, or who are unresponsive to T4-only therapy.
• Key competitors include brand-name formulations (e.g., Cytomel) and compounded T3 products with variable quality control.

Regulatory and Market Access Factors

• FDA approval for TIROSINT-SOL was granted in 2020.
• European and Asian markets have varying regulatory pathways, with some countries allowing over-the-counter access for compounded T3.
• Reimbursement policies favor T4 therapies; T3 formulations are often off-label or require prior authorization.

Pricing and Reimbursement Considerations

• Estimated wholesale price for TIROSINT-SOL is USD 200 per month retail in the US.
• Cost-effectiveness analyses indicate that T3 formulations are premium-priced, with limited reimbursement scope.

R&D and Manufacturing Fundamentals

• The manufacturing process involves synthesis of liothyronine sodium under GMP standards.
• Production costs are approximately 20% lower than comparable capsules due to formulation differences.
• The drug's chemical stability and bioavailability are comparable to traditional capsules.

Key Investment Considerations

Growth Opportunities

• Rising aging population and increased hypothyroidism diagnosis portend expanding demand.
• Growing preference for liquid formulations in specific patient groups enhances market penetration.
• Limited patent exclusivity; generic competition is anticipated within 3-5 years unless new formulations are developed.

Challenges and Risks

• Dominance of T4 therapy limits market share growth.
• Reimbursement hurdles may restrict patient access; healthcare payers favor cost-effective generics.
• Post-marketing safety reports could impact regulatory status or prescribing behaviors.

Competitive Advantages

• Liquid formulation improves compliance among patients with swallowing difficulties or malabsorption.
• Potential for expansion into pediatric or special populations with tailored dosing.
• Strategic collaborations with healthcare providers for targeted marketing.

Financial Metrics and Investment Timeline

• Licensing agreements or exclusive distribution arrangements could generate revenues of USD 50-100 million annually in mature markets.
• Margins are driven by manufacturing scale; gross margins estimated at 60%.
• Break-even expected within 2-3 years assuming steady sales growth.

Patent and Intellectual Property Status

• No current patents on the formulation expire in 2025.
• Pending patent applications for extended-release versions could extend market exclusivity until 2030.
• Patent disputes over bioequivalent formulations are unlikely due to clear chemical pathways.

Final Outlook

TIROSINT-SOL operates in a niche with moderate growth prospects. The drug benefits from clinical efficacy and patient compliance advantages in specific populations. Market adoption hinges on reimbursement policies, physician acceptance, and the competitive landscape dominated by existing T4 therapies. Investment should focus on securing distribution channels and monitoring regulatory developments that could influence market size and profitability.

Key Takeaways

• TIROSINT-SOL addresses specific patient needs but faces limited overall market share due to T4 dominance.
• Growing aging and hypothyroidism prevalence support long-term demand.
• Cost, reimbursement, and competition from generics present challenges.
• Strategic focus on liquid formulation benefits and niche expansion offers growth opportunities.
• Regulatory status and patent expiry timelines are critical to valuation.

FAQs

1. What is the primary advantage of TIROSINT-SOL over capsules?
   It offers improved compliance for patients with swallowing difficulties and better absorption in malabsorptive conditions.

2. Who are the main competitors?
   Traditional T4 therapies like levothyroxine and branded T3 products such as Cytomel.

3. What are the key regulatory hurdles?
   Reimbursement policies favor T4, and off-label use or premium pricing for T3 formulations may limit market access.

4. When are patent expiries expected?
   Basic formulations face expiries around 2025; extended-release patents could extend to 2030.

5. Is there potential for combination therapies?
   Yes; research into combined T3 and T4 formulations is ongoing but not yet commercially available.

---

References

[1] American Thyroid Association. (2022). Hypothyroidism in the United States. Retrieved from https://www.thyroid.org